TERT promoter mutation status in sarcomatoid urothelial carcinomas of the upper urinary tract

To determine TERT promoter mutation status as well as the expression of PAX8, GATA3, p63, p40, p53 and uroplakin III in 17 patients with the upper urinary tract sarcomatoid urothelial carcinoma.

 TERT C228T mutations were found in six of 17 cases (35%). p53 was expressed in 77% of these tumors. PAX8, GATA3, p40 and uroplakin III are less frequently expressed. Lymph node metastases were present in ten cases (59%). Eight patients (47%), including all three patients with TERT mutation, died of cancer within 2 years after surgery.

Sarcomatoid carcinoma of the upper urinary tract is an aggressive tumor and the presence of TERT mutation may portend poor prognosis.

Future oncology (London, England). 2017 Jan 05 [Epub ahead of print]

Xiaoyan Wang, Antonio Lopez-Beltran, Adeboye O Osunkoya, Mingsheng Wang, Shaobo Zhang, Darrell D Davidson, Robert E Emerson, Sean R Williamson, Puay-Hoon Tan, Hristos Z Kaimakliotis, Lee Ann Baldridge, Gregory T MacLennan, Rodolfo Montironi, Liang Cheng

Department of Pathology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Pathology & Surgery, Faculty of Medicine, Cordoba, Spain., Departments of Pathology & Urology, Emory University School of Medicine, Atlanta, GA, USA., Department of Pathology & Laboratory Medicine, Henry Ford Health System, Detroit, MI, USA., Department of Pathology, Singapore General Hospital, Singapore., Department of Urology, Indiana University School of Medicine, Indianapolis, IN, USA., Department of Pathology, Case Western Reserve University, Cleveland, OH, USA., Institute of Pathological Anatomy & Histopathology, School of Medicine, Polytechnic University of the Marche Region (Ancona), United Hospitals, Ancona, Italy.